|
|
|
|
| LEADER |
03679nmm a2200313 u 4500 |
| 001 |
EB002209899 |
| 003 |
EBX01000000000000001347099 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
240603 ||| eng |
| 020 |
|
|
|a 9783031545139
|
| 100 |
1 |
|
|a Feldman, Steven R.
|e [editor]
|
| 245 |
0 |
0 |
|a Management of Atopic Dermatitis
|h Elektronische Ressource
|b Methods and Challenges
|c edited by Steven R. Feldman, Lindsay C. Strowd, Katie K. Lovell
|
| 250 |
|
|
|a 2nd ed. 2024
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2024, 2024
|
| 300 |
|
|
|a X, 248 p. 9 illus., 7 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Introduction -- Atopic Dermatitis: Disease Background and Risk Factors -- Atopic Dermatitis: Pathophysiology -- Clinical Presentation of Atopic Dermatitis -- Special Considerations for Atopic Dermatitis in Skin of Color Patients -- Atopic Dermatitis Disease Complications -- The Psychosocial Impact of Atopic Dermatitis -- Stressors in Atopic Dermatitis -- The Economics Burden of Atopic Dermatitis -- Defining and Measuring the Scope of Atopic Dermatitis -- Topical Prescription Management (including new topical JAK) -- Oral Prescription Management (including new oral JAKs).-Introduction -- Atopic Dermatitis: Disease Background and Risk Factors -- Atopic Dermatitis: Pathophysiology -- Clinical Presentation of Atopic Dermatitis -- Special Considerations for Atopic Dermatitis in Skin of Color Patients -- Atopic Dermatitis Disease Complications -- The Psychosocial Impact of Atopic Dermatitis -- Stressors in Atopic Dermatitis -- The Economics Burden of Atopic Dermatitis -- Defining and Measuring the Scope of Atopic Dermatitis -- Topical Prescription Management (including new topical JAK) -- Oral Prescription Management (including new oral JAKs) -- Systemic Biologic Management (dupilumab and tralokinumab) -- Non-Prescription Treatment Options -- Adherence in Atopic Dermatitis -- Atopic Dermatitis: Managing the Itch -- Atopic Dermatitis Disease Education -- Guidelines from American Academy of Dermatology -- The Future of Atopic Dermatitis Treatment (to be updated—some drugs discussed in this chapter are now FDA approved)
|
| 653 |
|
|
|a Epidemiology
|
| 653 |
|
|
|a Dermatology
|
| 653 |
|
|
|a Pathology
|
| 700 |
1 |
|
|a Strowd, Lindsay C.
|e [editor]
|
| 700 |
1 |
|
|a Lovell, Katie K.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Advances in Experimental Medicine and Biology
|
| 028 |
5 |
0 |
|a 10.1007/978-3-031-54513-9
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-031-54513-9?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.5
|
| 520 |
|
|
|a This new edition builds upon the foundational knowledge covered in the first edition, covering the epidemiology, pathogenesis, and clinical presentation of atopic dermatitis in both pediatric and adult patients. It provides an overview of the mechanism and presentation of atopic dermatitis and focuses on the management methods experienced dermatologists have used to successfully manage atopic dermatitis. The book includes new chapters describing the special considerations for atopic dermatitis in skin of color patients, dedicated chapters on topical and oral prescription management reflected the latest FDA-approved treatments, and also a chapter covering the updated guidelines from the American Academy of Dermatology. A final chapter includes updates on the future of atopic dermatitis treatment. This book provides physicians with insights into the management of atopic dermatitis, such as alternative treatments for pruritus, psychosocial impact on patients and families, assessing patient compliance, and patient resources
|